Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03877510 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations
A Phase 3 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
NCT03877510 is a Phase 3 study that has completed, run by Impax Laboratories. The registered enrollment target is 419 participants.
The verdict
NCT03877510, a Phase 3 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
Interventions
- DRUG IPX203
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2019-04-03 |
| Est. Completion | 2022-03-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03877510
The ClinicalTrials.gov registry entry for NCT03877510 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPX203 is the first listed.
NCT03877510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03877510 about?
NCT03877510 is a clinical study titled "Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations". The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.
What is the current status of trial NCT03877510?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2019-04-03. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT03877510?
The interventions under investigation include: IPX203 (DRUG).
Who is sponsoring clinical trial NCT03877510?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.